Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Leases: 2021-2024

Historic Current Leases for Crinetics Pharmaceuticals (CRNX) over the last 4 years, with Dec 2024 value amounting to $7.2 million.

  • Crinetics Pharmaceuticals' Current Leases fell 13.11% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 13.11%. This contributed to the annual value of $7.2 million for FY2024, which is 71.39% up from last year.
  • As of FY2024, Crinetics Pharmaceuticals' Current Leases stood at $7.2 million, which was up 71.39% from $4.2 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Current Leases ranged from a high of $7.2 million in FY2024 and a low of $939,000 during FY2021.
  • For the 3-year period, Crinetics Pharmaceuticals' Current Leases averaged around $4.1 million, with its median value being $4.2 million (2023).
  • Data for Crinetics Pharmaceuticals' Current Leases shows a peak YoY skyrocketed of 297.05% (in 2023) over the last 5 years.
  • Crinetics Pharmaceuticals' Current Leases (Yearly) stood at $939,000 in 2021, then increased by 11.93% to $1.1 million in 2022, then skyrocketed by 297.05% to $4.2 million in 2023, then soared by 71.39% to $7.2 million in 2024.